Tivicay and Plasmablastic lymphoma - a phase IV clinical study of FDA data

Summary:

Plasmablastic lymphoma is reported as a side effect among people who take Tivicay (dolutegravir sodium), especially for people who are male, 40-49 old, also take Clopidogrel, and have Coronary heart disease.

The phase IV clinical study analyzes which people have Plasmablastic lymphoma when taking Tivicay. It is created by eHealthMe based on reports of 9,634 people who have side effects when taking Tivicay from the FDA, and is updated regularly.

What is Tivicay?

Tivicay has active ingredients of dolutegravir sodium. It is often used in hiv infection. eHealthMe is studying from 9,674 Tivicay users. Check the latest studies of Tivicay.

What is Plasmablastic lymphoma?

Plasmablastic lymphoma (aggressive b-cell cancer occurring mainly in the jaws and oral cavity) is found to be associated with 40 drugs and 76 conditions by eHealthMe. Check the latest studies of Plasmablastic lymphoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

9,634 people reported to have side effects when taking Tivicay.
Among them, 13 people (0.13%) have Plasmablastic lymphoma.

Could Tivicay cause Plasmablastic lymphoma?

Among these 13 people:

What is the gender of people who have Plasmablastic lymphoma when taking Tivicay? *

female: 0.0 %
male: 100 %

What is the age of people who have Plasmablastic lymphoma when taking Tivicay? *

What are other drugs people take besides Tivicay? *

What are other side effects people have besides Plasmablastic lymphoma? *

Neoplasm Progression (growth of tumour): 10 people, 76.92%
Weakness: 1 person, 7.69%
Urination - Painful: 1 person, 7.69%
Muscle Function Loss: 1 person, 7.69%
Lymphoma (cancer that begins in immune system cells): 1 person, 7.69%
Inflammation: 1 person, 7.69%
Hypoaesthesia (reduced sense of touch or sensation): 1 person, 7.69%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 1 person, 7.69%
Back Pain: 1 person, 7.69%
Atypical Mycobacterial Infection (infections caused by several types of mycobacterium similar to the germ that causes tuberculosis): 1 person, 7.69%

What are the existing conditions these people have? *

Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 10 people, 76.92%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 10 people, 76.92%
Iron Deficiency Anaemia: 2 people, 15.38%
Hepatitis B: 2 people, 15.38%
Atypical Mycobacterial Infection (infections caused by several types of mycobacterium similar to the germ that causes tuberculosis): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Tivicay and have Plasmablastic lymphoma?

- Check whether Plasmablastic lymphoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tivicay:

Tivicay (9,674 reports)

Browse all side effects of Tivicay:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Plasmablastic lymphoma:

Plasmablastic lymphoma (40 drugs)

Browse all the conditions that are associated with Plasmablastic lymphoma:

Plasmablastic lymphoma (76 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dolutegravir sodium (the active ingredients of Tivicay) and Tivicay (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.